SEATTLE, April 06, 2020 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the U.S. influenza vaccine market was valued at US$ 2.6 billion in 2019, and is expected to exhibit a CAGR of 16.1% during the forecast period (2019-2027).

Key Trends and Analysis of the U.S. Influenza Vaccine Market:

Increasing U.S. government initiatives, in order to support various research institutes who are engaged in research and development activities and focusing on the development of the novel flu vaccines. The government is providing financial support to the research institutes, in order to continue the research for developing universal influenza vaccine. For instance, in 2019, Center for Vaccine Development and Global Health (CVD) has awarded the total funding accounted for over US$ 200 million dollars to the researchers at University of Maryland School of Medicine (UMSOM). The main aim of the funding is to develop a universal vaccine to protect against emerging influenza strains as well as improvements to current seasonal vaccines.’

Request for Sample PDF copy @ https://www.coherentmarketinsights.com/insight/request-sample/1127

The rising adoption of inorganic growth strategies such as collaborations by the major key players and increasing focus on product development and manufacturing are expected to drive the market growth. For instance, in December 2018, Sanofi developed a new vaccine, similar to the Vaxelis, in partnership with Merck.

Moreover, constant improvements on formulation and production levels, by the key players for the development of influenza vaccines is expected to boost growth of the influenza vaccines market. For instance, according to the Centers for Disease Control and Prevention, in February 2020, for the 2019-2020 influenza season, it is estimated that, manufacturers will provide as many as 162 to 169 million doses of influenza vaccine for the U.S. market.

Key Market Takeaways:

Major players operating in the U.S. influenza vaccine market include—

Sanofi Pasteur, Seqirus Vaccines Ltd., GlaxoSmithKline Plc., and Medimmune

Buy this Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/1127

Market Segmentation:

Did not find what you were looking for? Here are similar topics:

GMP CELL BANKING SERVICES MARKET

GMP cell banking services is termed as the storing of cells of specific genome for the purpose of future use in a product or medicinal needs. Different types of cell lines stored in cell banks constitute of mammalian cells, microbial cells, insect cell lines, yeast cells, avian cells, and stem cells.

REGENERATIVE THERAPIES MARKET

Regenerative medicine is one the fastest emerging fields of medicine, as it adopts stem cells for treatment. Increasing age or injury, makes it difficult to provide the optimum amount of stem cells that are needed to maintain the normal function. The goal of regenerative medicine is to amplify this natural repair system to keep pace with the demands of the patients.

GLYCOBIOLOGY MARKET

Glycobiology involves study of structural aspects, biosynthesis, and biology of polysaccharides and how they function in an organism. Study of glycobiology has variety of application in areas such as drug discovery and development, diagnostic applications, therapeutic application, and industrial applications.

VIRAL VECTOR AND PLASMID DNA TESTING SERVICES MARKET

Viral vectors are the best approach used in the gene therapies and therefore, testing services are the key factors for the timely development of viral vector-based therapies. Viral vector characterization plays an important role for orthogonal analytical approaches. The characterization is significant through the regulatory perspective, which include product safety, identity, purity, and potency.

Mr. Shah
Coherent Market Insights
1001 4th Ave. 
#3200 
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com